About
Unlocking the Therapeutic Potential of Microbes to Treat the Most Challenging Diseases
MicThera is a biotechnology company pioneering microbial-inspired drug discovery to address diseases where current therapies fail. By unlocking nature’s vast and largely untapped biochemical arsenal, we develop first-in-class therapeutics with novel mechanisms of action.
Our proprietary platform translates microbial bioactives into clinically relevant drug candidates, enabling precision targeting of complex and drug-resistant conditions.
This approach underpins two high-value development programs:
🧬 Oncology Program
Developing breakthrough biologics targeting resistance mechanisms in advanced prostate cancer, including tumors unresponsive to current standard-of-care therapies.
🦠 Antimicrobial Program
Discovering novel anti-infective agents to combat antimicrobial resistance, one of the most urgent global health threats.
Our Approach
Harnessing Microbial Bioactives for Next-Generation Therapeutics
Microbes have evolved over millions of years to produce highly potent bioactive molecules capable of modulating complex biological systems. At MicThera, we systematically harness this untapped biological diversity to discover and develop first-in-class therapeutics for areas of high unmet medical need, starting with oncology.
Our approach integrates:
🔬 Advanced Discovery Platforms
We combine proprietary microbial screening, multi-omics analyses, and data-driven prioritization to identify bioactive molecules with strong therapeutic potential and novel mechanisms of action.
🧬 Translational-by-Design Development
From the earliest stages, our programs are built around human relevance. We rapidly translate microbial bioactives into drug-like candidates -such as engineered biologics- optimized for efficacy, safety, and clinical development.
🎯 Novel and High-Value Targets
We focus on previously underexplored targets and pathways that remain active in advanced and drug-resistant disease, enabling differentiated therapies where existing approaches fail.
